Welcome to our dedicated page for Terumo news (Ticker: TRUMY), a resource for investors and traders seeking the latest updates and insights on Terumo stock.
Terumo Corporation (TRUMY) is a global leader in medical technology, driving innovations in cardiovascular systems, blood therapies, and minimally invasive devices. This page serves as the definitive source for official company announcements and developments.
Access real-time updates on earnings reports, regulatory milestones, and strategic partnerships. Investors and healthcare professionals will find curated press releases detailing product launches, clinical trial outcomes, and operational expansions across Terumo’s three core divisions.
Our repository ensures you stay informed about advancements in plasma collection systems, interventional devices, and cardiac monitoring technologies. Bookmark this page for streamlined access to TRUMY’s latest initiatives shaping patient care worldwide.
Terumo Blood and Cell Technologies (Terumo BCT) has appointed Patrick Daly as its new Chief Business Officer. With over 30 years of healthcare industry experience, Daly joins from IQVIA where he built the MedTech Global Data franchise.
Prior to IQVIA, Daly served as President and CEO of Cohera Medical and currently maintains a position as independent Board Director for BioStem Technologies. His extensive career includes senior leadership roles at Johnson & Johnson in strategic marketing, sales, and business development. Daly holds a Bachelor of Science in Foreign Area Studies from West Point.
According to CEO Antoinette Gawin, Daly's expertise in capital acquisition, strategic partnerships, and data monetization positions him to integrate offerings and drive innovation. The appointment aligns with Terumo BCT's ambitions for double-digit growth and its mission to address global healthcare challenges through enhanced disease research, therapeutic development, and blood safety initiatives.
Terumo Health Outcomes (THO) has announced the U.S. availability of Medis QFR 3.0, an FDA-cleared software solution for coronary physiology assessment, through its collaboration with Medis Medical Imaging. The AI-powered software aims to enhance catheterization laboratory efficiency and patient comfort.
The technology has been extensively validated through over 200 peer-reviewed publications, with data from more than 17,000 patients and 20,000 lesions. Notably, QFR received recommendation from the European Society of Cardiology in their 2024 ESC Guidelines. THO will showcase QFR 3.0 at the upcoming SCAI 2025 Scientific Sessions.
This software integrates with THO's ePRISM platform, which provides predictive insights for patient risk assessment and treatment optimization, potentially reducing hospital costs and recovery times.
Terumo Neuro has achieved a significant milestone with FDA Premarket Approval (PMA) for its Carotid Stent System, marking the first dual-layer micromesh carotid stent approved in the United States. The innovative device is designed for treating carotid artery stenosis in patients who face increased risks from traditional carotid endarterectomy procedures.
The stent system is specifically indicated for treating patients with de novo atherosclerotic or post-endarterectomy restenotic lesions in internal carotid arteries or at the carotid bifurcation. It can be used in symptomatic patients with ≥50% stenosis or asymptomatic patients with ≥80% stenosis, as confirmed by angiography. The device is compatible with vessel reference diameters ranging from 3.5 mm to 9.0 mm at the target lesion.
Terumo Neuro celebrates the 15th anniversary of its WEB™ Aneurysm Embolization System, a revolutionary device that has transformed wide-neck bifurcation aneurysm treatment. Since its CE Mark approval and commercial launch in October 2010, over 25,000 devices have been implanted worldwide.
The WEB device, as the world's first intrasaccular flow disruptor, offers a single-device solution that minimizes the need for dual antiplatelet therapy. Its clinical success is backed by seven global Good Clinical Practice studies and over 200 peer-reviewed publications.
Key achievements include:
- Zero recorded rebleeds in WEB device-treated aneurysms across 1,464 patient-years
- 0% device-related morbidity and mortality in five-year follow-up data
- Introduction of WEB 17 system for treating smaller aneurysms
Terumo Neuro is showcasing its comprehensive stroke solutions portfolio at the International Stroke Conference (ISC) from February 4-7, 2025, in Los Angeles. The company is highlighting their integrated product line, including the anticipated SOFIA™ 88 Neurovascular Support Catheter, which will be featured in a symposium led by Dr. Ameer E. Hassan on February 6th.
The showcased portfolio includes: SOFIA™ Catheters for trackability and clinical performance, ERIC™ Retrieval Device for ischemic stroke treatment, BOBBY™ Balloon Guide Catheter for flow arrest, WEDGE™ Microcatheter for smooth navigation, HEADWAY™ Microcatheters for excellent trackability, and TRAXCESS™ Guidewire for challenging anatomies.
Terumo Health Outcomes (THO) and Medis Medical Imaging have announced a strategic partnership in the United States to enhance cardiovascular care. The collaboration combines THO's ePRISM clinical decision support platform with Medis' Quantitative Flow Ratio (QFR) technology, a non-invasive software for assessing coronary physiology.
The partnership will pilot at selected clinical sites, using real-time electronic health records data. Medis QFR has shown promising results in the FAVOR trials, demonstrating a 34% reduction in major adverse cardiac events compared to standard procedures. The technology has received approval in Japan and is included in the 2024 ESC guidelines with a Class I recommendation.
The PIONEER IV trial, involving 2,540 patients, will evaluate the next-generation QFR technology's integration with THO's ePRISM platform.
Terumo Interventional Systems has launched its R2P NaviCross peripheral support catheter in the U.S., expanding its radial-to-peripheral portfolio. The new 200 cm length catheter features double-braided, stainless-steel construction for enhanced trackability and torque control in complex procedures. This addition complements Terumo's existing R2P portfolio, which includes the Destination Slender guiding sheath, SlenGuide guiding catheter, Misago self-expanding peripheral stent, and other specialized catheters. The device is specifically designed for treating peripheral artery disease (PAD) and critical limb ischemia through radial access procedures.
Terumo Blood and Cell Technologies has completed a meta-analysis demonstrating the effectiveness of automated red blood cell exchange (aRBCX) in improving quality of life for sickle cell disease (SCD) patients. The study, published in Vox Sanguinis, analyzed over two decades of research and showed that aRBCX leads to shorter hospital stays, reduced procedure times, and fewer pain-related hospitalizations.
The research supports patient testimonials about aRBCX's benefits in managing SCD complications. The company's Spectra Optia™ Apheresis System is used to remove sickled cells from patients' blood. The study also highlighted the need for further research on psychosocial aspects of treatment.
Terumo has established Terumo Ventures, a Corporate Venture Capital (CVC) organization within Terumo Americas Holding, aimed at leading the Group's venture investments. Terumo Ventures will invest US$ 75 million over the next five years in early-stage companies in fields like cardiovascular disease, chronic disease treatment, and digital technologies. The CVC operates in global innovation hubs, such as Massachusetts and California.
Since 2013, Terumo has been building relationships with medtech start-ups through investments in venture capital funds in the US and China. The new CVC aims to increase agility in identifying and executing venture investments, accelerating the acquisition of cutting-edge technologies, and developing a robust M&A pipeline.
Aligned with its 5-Year Growth Strategy 'GS26' and long-term vision 'From Devices to Solutions,' Terumo aims to enhance innovation capabilities. This includes a new director position managing innovation-related functions and fostering cross-functional collaboration.
Terumo Cardiovascular announced that the U.S. FDA has granted 510(k) clearance for its CDI OneView Monitoring System. This next-generation platform can measure and display up to 22 key patient parameters during cardiopulmonary bypass surgery, enhancing perfusion safety and patient outcomes. Key new parameters include measured flow (Q), cardiac index (CI), and regional cerebral oxygen saturation (rSO2). The system's modular design allows for flexible configuration to meet clinical needs. Terumo emphasized the system's development was influenced by extensive feedback from global cardiovascular experts and is aimed at reducing complications such as acute kidney injury.
